122 related articles for article (PubMed ID: 12168843)
1. Identification and relationship of HER-2/neu overexpression to short-term mortality in primary malignant brain tumors.
Forseen SE; Potti A; Koka V; Koch M; Fraiman G; Levitt R
Anticancer Res; 2002; 22(3):1599-602. PubMed ID: 12168843
[TBL] [Abstract][Full Text] [Related]
2. Role of Her-2/neu overexpression and clinical determinants of early mortality in glioblastoma multiforme.
Koka V; Potti A; Forseen SE; Pervez H; Fraiman GN; Koch M; Levitt R
Am J Clin Oncol; 2003 Aug; 26(4):332-5. PubMed ID: 12902879
[TBL] [Abstract][Full Text] [Related]
3. Role of immunohistochemical identification of Her-2/neu and detection of variability in overexpression in pancreatic carcinoma.
Koka V; Potti A; Koch M; Fraiman G; Mehdi S; Levitt R
Anticancer Res; 2002; 22(3):1593-7. PubMed ID: 12168842
[TBL] [Abstract][Full Text] [Related]
4. Determination of HER-2/neu overexpression and clinical predictors of survival in a cohort of 347 patients with primary malignant brain tumors.
Potti A; Forseen SE; Koka VK; Pervez H; Koch M; Fraiman G; Mehdi SA; Levitt R
Cancer Invest; 2004; 22(4):537-44. PubMed ID: 15565811
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical determination of HER-2/neu in malignant melanoma.
Potti A; Hille R; Koch M
Anticancer Res; 2003; 23(5A):4067-9. PubMed ID: 14666720
[TBL] [Abstract][Full Text] [Related]
6. Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors.
Jimenez RE; Hussain M; Bianco FJ; Vaishampayan U; Tabazcka P; Sakr WA; Pontes JE; Wood DP; Grignon DJ
Clin Cancer Res; 2001 Aug; 7(8):2440-7. PubMed ID: 11489824
[TBL] [Abstract][Full Text] [Related]
7. Effect of pesticide exposure on HER-2/neu overexpression seen in patients with extensive stage small cell lung carcinoma.
Potti A; Ganti AK; Sholes K; Langness E; Koka V; Horvarth L; Koch M
Clin Cancer Res; 2003 Oct; 9(13):4872-6. PubMed ID: 14581360
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical detection of HER-2/neu, c-kit (CD117) and vascular endothelial growth factor (VEGF) overexpression in soft tissue sarcomas.
Potti A; Ganti AK; Foster H; Knox S; Hebert BJ; Tendulkar K; Sholes K; Koch M; Kargas S
Anticancer Res; 2004; 24(1):333-7. PubMed ID: 15015617
[TBL] [Abstract][Full Text] [Related]
9. Expression of HER-2/neu in testicular tumors.
Mandoky L; Geczi L; Bodrogi I; Toth J; Bak M
Anticancer Res; 2003; 23(4):3447-51. PubMed ID: 12926088
[TBL] [Abstract][Full Text] [Related]
10. HER-2/neu overexpression in breast cancer: an immunohistochemical study including correlations with clinicopathologic parameters, p53 oncoprotein and cathepsin-D.
Korkolis D; Ardavanis A; Yotis J; Kyroudi A; Gorgoulis V; Kittas C
Anticancer Res; 2001; 21(3C):2207-12. PubMed ID: 11501848
[TBL] [Abstract][Full Text] [Related]
11. The prognostic and predictive value of immunohistochemically detected HER-2/neu overexpression in 361 patients with ovarian cancer: a multicenter study.
Riener EK; Arnold N; Kommoss F; Lauinger S; Pfisterer J
Gynecol Oncol; 2004 Oct; 95(1):89-94. PubMed ID: 15385115
[TBL] [Abstract][Full Text] [Related]
12. Clinical relevance of HER-2/neu expression in germ-cell testicular tumors.
Mándoky L; Géczi L; Bodrogi I; Tóth J; Csuka O; Kásler M; Bak M
Anticancer Res; 2004; 24(4):2219-24. PubMed ID: 15330164
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of Her-2/neu overexpression in uterine serous carcinoma.
Díaz-Montes TP; Ji H; Smith Sehdev AE; Zahurak ML; Kurman RJ; Armstrong DK; Bristow RE
Gynecol Oncol; 2006 Jan; 100(1):139-44. PubMed ID: 16182348
[TBL] [Abstract][Full Text] [Related]
14. Her-2/neu expression and gene amplification in gastrinomas: correlations with tumor biology, growth, and aggressiveness.
Goebel SU; Iwamoto M; Raffeld M; Gibril F; Hou W; Serrano J; Jensen RT
Cancer Res; 2002 Jul; 62(13):3702-10. PubMed ID: 12097278
[TBL] [Abstract][Full Text] [Related]
15. Prognostic and predictive impact of the HER-2/ neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer.
Müller V; Witzel I; Lück HJ; Köhler G; von Minckwitz G; Möbus V; Sattler D; Wilczak W; Löning T; Jänicke F; Pantel K; Thomssen C
Breast Cancer Res Treat; 2004 Jul; 86(1):9-18. PubMed ID: 15218357
[TBL] [Abstract][Full Text] [Related]
16. Do we need HER-2/neu testing for all patients with primary breast carcinoma?
Taucher S; Rudas M; Mader RM; Gnant M; Dubsky P; Bachleitner T; Roka S; Fitzal F; Kandioler D; Sporn E; Friedl J; Mittlböck M; Jakesz R
Cancer; 2003 Dec; 98(12):2547-53. PubMed ID: 14669272
[TBL] [Abstract][Full Text] [Related]
17. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.
Korkolis DP; Tsoli E; Fouskakis D; Yiotis J; Koullias GJ; Giannopoulos D; Papalambros E; Nikiteas NI; Spiliopoulou CA; Patsouris E; Asimacopoulos P; Gorgoulis VG
Anticancer Res; 2004; 24(3b):2061-8. PubMed ID: 15274401
[TBL] [Abstract][Full Text] [Related]
18. Primary breast cancer phenotypes associated with propensity for central nervous system metastases.
Tham YL; Sexton K; Kramer R; Hilsenbeck S; Elledge R
Cancer; 2006 Aug; 107(4):696-704. PubMed ID: 16826579
[TBL] [Abstract][Full Text] [Related]
19. HER-2/neu and CD117 (C-kit) overexpression in hepatocellular and pancreatic carcinoma.
Potti A; Ganti AK; Tendulkar K; Chitajallu S; Sholes K; Koch M; Kargas S
Anticancer Res; 2003; 23(3B):2671-4. PubMed ID: 12894556
[TBL] [Abstract][Full Text] [Related]
20. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma.
Santin AD; Bellone S; Van Stedum S; Bushen W; Palmieri M; Siegel ER; De Las Casas LE; Roman JJ; Burnett A; Pecorelli S
Cancer; 2005 Oct; 104(7):1391-7. PubMed ID: 16116605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
